Want to see ABEO full AI Analyst Report?
ABEO Stock Chart & Stats
$5.92
$0.08(1.32%)
At close: 4:00 PM EDT
$5.92
$0.08(1.32%)
Day’s Range― - ―
52-Week Range$4.00 - $7.65
Previous Close$6.13
Volume779.34K
Average Volume (3M)1.40M
Market Cap
$252.18M
Enterprise Value$225.61M
Total Cash (Recent Filing)$146.83M
Total Debt (Recent Filing)$19.87M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 16, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding57,184,017
10 Day Avg. Volume1,318,922
30 Day Avg. Volume1,398,581
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue8.84
Enterprise Value/Gross Profit15.61
Enterprise Value/Ebitda-3.16
Forecast
1Y Price Target
$22.00Price Target Upside271.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.98
Revenue Forecast (FY)$50.72M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthRevenue growth alongside five Q2 patient treatments and seven activated centers indicates that ZEVASKYN is progressing from launch toward a broader commercial operating model. Continued patient adoption and center utilization could establish a more durable revenue base over the next several quarters.
Reimbursement SupportThe NTAP award provides supplemental hospital reimbursement beginning in FY2027 and externally validates the therapy’s clinical improvement. That support may reduce payment friction for eligible cases, strengthen hospital adoption, and improve the durability of the commercial rollout.
Modest Leverage And Financial FlexibilityLow leverage gives Abeona more balance-sheet flexibility than a heavily indebted biotechnology company while it scales its commercial product and funds development work. The limited debt burden can reduce refinancing pressure and preserve greater latitude for operating and capital-allocation decisions.
Bears Say
Heavy Cash Burn And Persistent LossesAbeona is not yet funding operations from internally generated cash, and substantial operating losses make the business dependent on improving commercialization or obtaining external financing. Continued burn can erode equity and constrain investment capacity if profitability does not improve.
Manufacturing Yield And Billing RiskManufacturing failures can create a direct mismatch between clinical activity and reported revenue while Abeona still absorbs production costs. Repeated low-yield or out-of-specification batches would weaken margins, increase revenue volatility, and make the commercial ramp less predictable.
Regulatory And Operational Execution ComplexityThe assay-specification issue creates regulatory timing uncertainty, while the short shelf life increases coordination requirements across treatment stakeholders. Together, these execution demands can delay treatments, disrupt center throughput, and slow the conversion of clinical demand into dependable revenue.
Abeona Therapeutics News
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $4.00 and its highest was $7.65 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $252.18M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 26 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.232 by -$0.118.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 57,184,017 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.232. Following the earnings report the stock price went down -14.946%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in ABEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (271.62% Upside)
$22.00 (271.62% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 92%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 40.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $305.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.02%
12-Months-Change
Fundamentals
Return on Equity
-41.69%
Trailing 12-Months
Asset Growth
-27.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
ABEO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights clear commercial progress: 31% quarter-over-quarter revenue growth, expansion to 7 QTCs, 12 patients treated since launch, improved average manufacturing yields in commercial runs, a strong balance sheet ($146.8M) and a significant NTAP reimbursement win that validates the therapy. However, material operational and manufacturing challenges (one low-yield and one out-of-spec batch causing unrevenueed treatments), logistical fragility around the 84-hour shelf life, regulatory work to revisit an assay specification, and continued GAAP losses introduce meaningful near-term execution risk and revenue volatility. Management has implemented clearer reporting metrics and is pursuing operational learnings to mitigate these issues, but variability in site activation and sensitivity to manufacturing yield remain key risks to the revenue ramp.View all ABEO earnings summariesABEO Stock 12 Month Forecast
Average Price Target
$22.00
▲(271.62% Upside)
Technical Analysis
Ownership Overview
6.19% Insiders
6.72% Mutual Funds
0.03% Other Institutional Investors
77.92% Public Companies and
Individual Investors